Top

Taking a novel approach to drug development

Twitter

Media

Scroll Down

AI is helping researchers fast-track discovering life-saving drugs

Read Now
Download Now

Lung Cancer Treatment for Never Smokers: The HARMONIC Phase 2 Trial and LP-300

Read Now
Download Now

LP-300 Plus Chemo Yields Early Efficacy Results in Never-Smokers With NSCLC

Read Now
Download Now

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Read Now
Download Now

LP-300 Shows Promise in Treating Advanced Lung Cancer in Never Smokers

Read Now
Download Now

How AI is transforming drug discovery

Read Now
Download Now

Lantern Pharma's Pioneering Role in AI-Driven Oncology Drug Development with the RADR® Platform

Read Now
Download Now

Behind the powerful computations, AI’s role in pharma is still beset by challenges

Read Now
Download Now

Putting LP-284 on the Industry RADR

Read Now
Download Now

Lantern Pharma is harnessing the power of AI and Machine Learning to Fight Cancer

Read Now
Download Now

How Lantern Pharma’s AI Is Changing the Game

Read Now
Download Now

Lantern Pharma aims to take drug to phase 3 for $100-200 million with AI-powered approach

Read Now
Download Now

Lantern Pharma Targets Surprising Group For Lung Cancer Screenings

Read Now
Download Now

The trends that will shape the biotech industry in 2024

Read Now
Download Now

Navigating the Crossroads of AI and Oncology: A Deep Dive with Lantern Pharma's CEO, Panna Sharma

Read Now
Download Now

FDA Grants Orphan Drug Designation to LP-284 for High-Grade B-Cell Lymphomas

Read Now
Download Now

How Lantern Pharma and Code Ocean partnered on oncology drug development

Read Now
Download Now

FDA Grants Orphan Drug Designation to LP-284 for Treatment of HGBL With MYC, BCL2 Rearrangements

Read Now
Download Now

Building a Path to Cure for Patients With NSCLC Who Have Never Smoked

Read Now
Download Now

Lantern Pharma doses first patient in solid tumour drug trial

Read Now
Download Now

AI Breaches the Barrier Towards Better CNS Drug Discovery

Read Now
Download Now

9 Notable AI Companies in Clinical Research to Watch in 2023

Read Now
Download Now

Using AI in the Development of Novel ADCs: Lantern Pharma and Bielefeld University to Cooperate

Read Now
Download Now

Lantern Pharma Offers AI Platform for ADC Discovery with Bielefeld University

Read Now
Download Now

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

Read Now
Download Now

Lantern Pharma to Study LP-184 in DNA Damage Response-Deficient Solid Tumors

Read Now
Download Now

Dallas firm’s experimental cancer drug set to begin human trials this summer

Read Now
Download Now

Unveiling Lantern Pharma's Success Story in AI-powered Precision Oncology

Read Now
Download Now

Lantern Pharma launches a cutting-edge AI algorithm

Read Now
Download Now

Busting the Brain’s Firewall: How Lantern Pharma’s Algorithms Can Predict a Drug’s Ability to Reach the Brain

Read Now
Download Now

Lantern Pharma Preparing IND for Synthetic Lethality Program With FDA Feedback

Read Now
Download Now

FDA Grants Orphan Drug Designation to LP-284 for Mantle Cell Lymphoma

Read Now
Download Now

LP-284 Exhibits Preclinical Efficacy in DDR-Deficient MCL

Read Now
Download Now

Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise

Read Now
Download Now

Powering Cancer Drug Discovery and Development Using the Artificial Intelligence and Machine Learning Platform RADR®

Read Now
Download Now

BPT20: Artificial Intelligence in Drug Discovery Productivity Index

Read Now
Download Now

LP-284 Shows Preclinical Activity in ATM-Mutated MCL

Read Now
Download Now

Lantern Pharma releases positive Preclinical Data on Efficacy of LP-284 for Mantle Cell Lymphoma

Read Now
Download Now

Highs and lows of drug repurposing

Read Now
Download Now

Study Finds New Synthetic Lethal Agent Could Be Potential Treatment for Pancreatic Cancer

Read Now
Download Now

Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate

Read Now
Download Now

Lantern Pharma's New Phase 2 Clinical Trial –Harmonic™ — Approved for Launch by the FDA

Read Now
Download Now

Lantern Pharma Gets FDA Nod to Begin Phase II Trial of LP-300 in Biomarker-Defined NSCLC

Read Now
Download Now

Lantern Pharma: transforming oncology drug development with AI

Read Now
Download Now

Nearly 300 Novel Agents Currently in Development for Rare Cancers

Read Now
Download Now

This Pharma Company Is Using Machine Learning And AI To Attempt To Transform Oncology Drug Development Processes

Read Now
Download Now

Lantern Pharma is Using Artificial Intelligence to Develop Oncology Treatments

Read Now
Download Now

Episode 703: Panna Sharma on Leveraging Artificial Intelligence To Rescue and Develop Cancer Therapies

Action & Ambition Podcast

Read Now
Download Now

Lantern Pharma and NCI expand oncology partnership

Read Now
Download Now

Lantern Pharma Collaborating With Danish Cancer Research Center on Drugs for NER-Deficient Tumors

Read Now
Download Now

Lantern Pharma Receives Rare Pediatric Disease and Orphan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT)

Read Now
Download Now

Lantern Pharma rises 9% on team up with National Cancer Institute for drug candidates

Read Now
Download Now

Lantern Pharma (LTRN) Reports Positive Efficacy Data of LP-284 in Hematologic Cancers

Read Now
Download Now

What is the Real Cost of Developing Medicine?

Healthcare Americana Podcast

Read Now
Download Now

Dallas region sees growing traction around the life sciences amid IPOs, fundings

Read Now
Download Now

Biotech is sprouting into Dallas-Fort Worth’s next big thing, based on seeds planted decades ago

Read Now
Download Now

Cost of Care: Defanged drug pricing reform means less of a bite for Big Pharma

Read Now
Download Now

BioBoss Podcast #39 - Panna Sharma, CEO of Lantern Pharma

Read Now
Download Now

Benzinga's Power Hour Show

Read Now
Download Now

The AI Pharmacist: How Artificial Intelligence Can Accelerate Drug Development

Read Now
Download Now

Slice of Healthcare Podcast #192 – Panna Sharma, CEO & President at Lantern Pharma

Read Now
Download Now

The Local Oncology Innovator ‘Smashing’ Drug Development Timelines

Read Now
Download Now

Why we are on the cusp of a golden age of medicine

Read Now
Download Now

Behind the Study: Retaining Nanomolar Potency in Lung Cancer

Read Now
Download Now

How Technologies Like AI and Machine Learning Can Help With the Development of Medicine

TradeTalks Video Broadcasts - With Jill Malandrino

Read Now
Download Now

Lantern Pharma, Fox Chase Partner on Pancreatic Cancer Drug, Search for Predictive Gene Signature

Read Now
Download Now

What going public means for Lantern Pharma

Read Now
Download Now

Episode 68: Rocking Garage Biotech

Read Now
Download Now

Dallas’ Lantern Pharma Hits Major Milestone on its AI Platform to Advance its Oncology Drug Research and Development

Read Now
Download Now

Midday Hot Stocks: SPCE falls as Bezos flies; HAL, UBS rise on earnings; LTRN gets strong pre-clinical data

Read Now
Download Now

Preclinical Data on New Pancreatic Cancer Drug Shines with over 90% Efficacy

Read Now
Download Now

Allarity Therapeutics, Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven

Read Now
Download Now

How AI Is Expediting Medicine Development

Read Now
Download Now

Lantern Pharma CEO Shares His Four Secrets to Turning a Startup into an IPO

Read Now
Download Now

How AI Is Transforming the Healthcare Landscape & Accelerating the Development of Medicine

Read Now
Download Now

Lantern ($LTRN) Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with

Read Now
Download Now

AI offers promise but faces barriers in drug development

Read Now
Download Now

Technology Is Rapidly Changing Cancer Care

Read Now
Download Now

Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company’s Progress in the Development of Biopharma Collaborations and Partnerships and Advancing

Read Now
Download Now

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern’s Artificial Intelligence Platform

Read Now
Download Now

New Lantern Manuscript: The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations

Read Now
Download Now

A machine learning‐based gene signature of response to the novel alkylating agent LP‐184 distinguishes its potential tumor indications

Read Now
Download Now

Join our team and help transform the cancer drug development process, cost and timeline!

Read Now
Download Now

By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.